Wall Street Zen Upgrades Rallybio (NASDAQ:RLYB) to “Hold”

Rallybio (NASDAQ:RLYB) was upgraded by equities researchers at Wall Street Zen from a “sell” rating to a “hold” rating in a report released on Saturday.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Rallybio in a research report on Saturday, September 27th. Four investment analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Reduce” and a consensus price target of $5.00.

Rallybio Stock Performance

Shares of RLYB opened at $0.56 on Friday. The company’s 50 day moving average price is $0.56 and its 200 day moving average price is $0.44. Rallybio has a 52 week low of $0.22 and a 52 week high of $1.24. The company has a market capitalization of $23.60 million, a PE ratio of -0.60 and a beta of -1.10.

Rallybio (NASDAQ:RLYB) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($0.22) EPS for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.02. Rallybio had a negative net margin of 5,473.33% and a negative return on equity of 71.66%. The firm had revenue of $0.21 million for the quarter. On average, equities analysts forecast that Rallybio will post -1.34 earnings per share for the current fiscal year.

About Rallybio

Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT.